ReviewBiological psychiatry2014
Modeling heterogeneous patients with a clinical diagnosis of schizophrenia with induced pluripotent stem cells.
Review in Biological psychiatry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Mental health dished up-the use of iPSC models in neuropsychiatric research.Journal of neural transmission (Vienna, Austria : 1996) · 2020Pooled it
- Modeling common and rare genetic risk factors of neuropsychiatric disorders in human induced pluripotent stem cells.Schizophrenia research · 2024Review
- Excitatory Dysfunction Drives Network and Calcium Handling Deficits in 16p11.2 Duplication Schizophrenia Induced Pluripotent Stem Cell-Derived Neurons.Biological psychiatry · 2023Article
- Review
- Autism NPCs from both idiopathic and CNV 16p11.2 deletion patients exhibit dysregulation of proliferation and mitogenic responses.Stem cell reports · 2022Article
- Time to re-engage psychiatric drug discovery by strengthening confidence in preclinical psychopharmacology.Psychopharmacology · 2021Review
- Association Between Abundance ofFrontiers in psychiatry · 2021Article
- Atypical Antipsychotic Drug Ziprasidone Protects against Rotenone-Induced Neurotoxicity: An In Vitro Study.Molecules (Basel, Switzerland) · 2020Article
- Integrative network analysis reveals biological pathways associated with Williams syndrome.Journal of child psychology and psychiatry, and allied disciplines · 2019Article
- Studying and modulating schizophrenia-associated dysfunctions of oligodendrocytes with patient-specific cell systems.NPJ schizophrenia · 2018Review
- Chromosomal Conformations and Epigenomic Regulation in Schizophrenia.Progress in molecular biology and translational science · 2018Review
- Genetic insights into the neurodevelopmental origins of schizophrenia.Nature reviews. Neuroscience · 2017Review
- Patient-derived hiPSC neurons with heterozygous CNTNAP2 deletions display altered neuronal gene expression and network activity.NPJ schizophrenia · 2017Article
- The epigenomics of schizophrenia, in the mouse.American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics · 2017Review
- Common developmental genome deprogramming in schizophrenia - Role of Integrative Nuclear FGFR1 Signaling (INFS).Schizophrenia research · 2017Article
- Low-Density Neuronal Cultures from Human Induced Pluripotent Stem Cells.Molecular neuropsychiatry · 2017Article
- Genetic evidence for role of integration of fast and slow neurotransmission in schizophrenia.Molecular psychiatry · 2017Review
- Using hiPSCs to model neuropsychiatric copy number variations (CNVs) has potential to reveal underlying disease mechanisms.Brain research · 2017Review
- The Importance of Non-neuronal Cell Types in hiPSC-Based Disease Modeling and Drug Screening.Frontiers in cell and developmental biology · 2017Review
- Molecular signatures associated with cognitive deficits in schizophrenia: a study of biopsied olfactory neural epithelium.Translational psychiatry · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Schizophrenia (SZ) is a devastating complex genetic mental condition that is heterogeneous in terms of clinical etiologies, symptoms, and outcomes. Despite decades of postmortem, neuroimaging, pharmacological, and genetic studies of patients, in addition to animal models, much of the biological mechanisms that underlie the pathology of SZ remain unknown. The ability to reprogram adult somatic cells into human induced pluripotent stem cells (hiPSCs) provides a new tool that supplies live human neurons for modeling complex genetic conditions such as SZ. The purpose of this review is to discuss the technical and clinical constraints currently limiting hiPSC-based studies. We posit that reducing the clinical heterogeneity of hiPSC-based studies, by selecting subjects with common clinical manifestations or rare genetic variants, will help our ability to draw meaningful insights from the necessarily small patient cohorts that can be studied at this time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.